Riskpilot← Back to searchSign inGet full accessDrug Development Consulting BidCo ApS
APSActiveCVR 42287067Smedeland 36Business and other management consultancy activities · NACE 7020Est. 20211 employees
Revenue 2024
DKK 3,4M
+48% vs 2023
EBITDA margin
20.8%
+215% vs 2023
Equity ratio
62.7%
Financial strength
Net profit 2024
DKK -13,2M
-41% vs 2023
| Revenue | DKK 3,4M | +48% |
| EBITDA | DKK 714K | +215% |
| Net profit | DKK -13,2M | -41% |
| Total assets | DKK 126M | +4% |
| Equity | DKK 79M | +12% |
| Employees | 1 | — |
Legal name
Drug Development Consulting BidCo ApS
CVR number
42287067
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
8. april 2021
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, af to medlemmer af bestyrelsen eller af en direktør i forening med bestyrelsens formand.
Company purpose
Selskabets formål er at eje kapitalandele i andre selskaber og anden i forbindelse hermed stående virksomhed, inklusiv, men ikke begrænset til, at yde management services til selskaber ejet fuldt eller delvist af selskabet.
Address
Smedeland 36
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -4.389 | 3.760 | 2.320 | 3.438 |
| Staff expenses | -931 | -1.938 | -2.942 | -2.724 |
| EBITDA | -5.320 | 1.822 | -622 | 714 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -5.320 | 1.822 | -622 | 714 |
| Net financials | -10.783 | -14.390 | -9.708 | -14.630 |
| Profit before tax | -15.401 | -12.568 | -10.330 | -13.916 |
| Tax | 351 | -737 | -949 | -701 |
| Net profit | -15.752 | -11.831 | -9.381 | -13.215 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 129.982 | 124.307 | 120.669 | 126.045 |
| Equity | 70.809 | 71.831 | 70.212 | 78.983 |
| Long-term debt | 53.630 | 48.310 | 45.590 | 0 |
| Short-term debt | 5.543 | 4.166 | 4.867 | 47.062 |
| Total debt | 59.173 | 52.476 | 50.457 | 47.062 |
EBITDA margin
20.8%
This company
15.8%
Market median
+32% vs market
20212024
Equity ratio
62.7%
This company
38.2%
Market median
+64% vs market
20212024
Return on equity
-16.7%
This company
18.4%
Market median
-191% vs market
20212024
Net profit margin
-384.4%
This company
8.1%
Market median
-4846% vs market
20212024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20212024
Debt / equity
0.60×
This company
0.62×
Market median
+3% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-04-08 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Management | Management | 2021 | — | — |
RK Management | Management | 2023 | — | — |
RH Management | Management | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Drug Development Consulting Holding ApS | Company | 100.0% | 100.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DDC Mørk Holding ApSDrug Development Consulting Holding ApS
Drug Development Consulting BidCo ApS (this company)Board members of Drug Development Consulting BidCo ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jasper Michiel van Gorp | Management | 0 companies |
| Rasmus Koch Nelund | Management | 0 companies |
| René Holmen Pedersen | Management | 0 companies |
| Mette Kirstine Agger | Board of Directors | 0 companies |
| Rafael Natanek | Board of Directors | 0 companies |
| Niels Peder Nielsen | Chairman | 0 companies |
| Alejandra Maria Cristina Bonifacini Mørk | Board of Directors | 0 companies |
| Redmar Koene | Board of Directors | 0 companies |